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Photodynamic Therapy, a new approach 
in the treatment of oral cancer
Terapia Fotodinámica, un nuevo acercamiento 
en el tratamiento del cáncer oral
Leandro Santos Bicalho1, João Paulo Figueiró Longo1, Luciana Oliveira Pereira1,
Maria de Fátima Meneses de Almeida Santos1, Ricardo Bentes Azevedo1
RESUMÉN
La incidencia del cáncer de cabeza y cuello es aproximadamente 640.000 casos nuevos por año. El 
cáncer oral representa un tercio de todos los cánceres y es el octavo más diagnosticado en hombres. Los 
tratamientos más usados para estos tumores son la cirugía, radioterapia, quimioterapia, o una combinación 
de estas modalidades terapéuticas. Debido al gran deterioro estructural, funcional y estético que causan 
los tratamientos convencionales, muchos estudios buscan nuevos métodos para remplazar o asistir el 
tratamiento del cáncer oral. La terapia fotodinámica (PDT) es una nueva modalidad promisoria en el 
tratamiento del cáncer que apenas está siendo usada clínicamente. Este artículo describe el uso de PDT 
como una alternativa para el tratamiento del cáncer oral. Salud UIS 2010; 42: 167-174
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ABSTRACT
The worldwide incidence of head and neck cancer is, approximately, 640,000 new cases per year. Oral cancer 
accounts for one third of all cancers and it is the eighth most diagnosed in men. The most used treatments for 
these tumors are surgery, radiotherapy, chemotherapy, or a combination of these therapeutic modalities. Due to 
the large structural, functional and aesthetic impairment that conventional treatments cause, many studies seek 
new methods to replace or to assist the treatment of oral cancer. Photodynamic therapy (PDT) is a promising 
new modality of cancer treatment that is already being used clinically. This article describes the use of PDT as 
an alternative for the treatment of oral cancer. Salud UIS 2010; 42: 167-174
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CANCER
The harmonization of several processes involved in the 
proliferation and differentiation of cells is indispensable 
for the development and maintenance of the organism. 
The disruption of this integration can result in a number 
of diseases, including cancer, a generic term that covers 
more than 200 kinds of diseases. Currently, cancer 
has become one of the most important public health 
problems worldwide. Epidemiological data indicate 
that malignancies are the third leading cause of death in 
the world and the second among the diseases1.
According to the report of the International Agency for 
Research on Cancer (IARC) / WHO (World Cancer 
Report, 2008)2, the overall impact of cancer more than 
doubled in 30 years. Currently, cancer is one of the most 
common causes of morbidity and mortality worldwide. 
It has been reported over 10 million new cases and 
over 6 million deaths per year. Over 20 million people 
worldwide are living with a diagnosis of cancer and 
more than half of all cancer cases occur in developing 
countries. The continued population growth, as well as 
their aging, affect significantly the impact of cancer in 
the world. This impact will primarily have an effect on 
the countries of medium and low development levels. 
The IARC / WHO estimated that half of new cases 
and nearly two thirds of cancer deaths occur in these 
locations3.
Cancer is a terminology known worldwide for a variety 
of diseases that have in common the proliferation 
of specific cell populations, with potential to invade 
nearby and/or distant tissues. In pathological terms, 
cancer is classified as a malignant neoplasm. In other 
words, it is the development of new cell clones with 
greater proliferative activity than neighboring cells and 
with severe invasive and destructive potential4.
Normal cells proliferate as a result of a biochemical 
balance between growth factors and inhibitors. These 
factors reach the cells through the circulation and 
from neighboring cells. Cancer cells are not affected 
by these regulatory mechanisms, following its own 
internal control for replication. Thus, their growth is 
unrestricted and these cells can escape from senescence 
and cell death programs5.
Some authors describe the development of cancer as a 
microevolutionary process at cellular scale, where one 
of the billions of cells in the human body develops a new 
feature that allows a higher proliferative activity despite 
the inhibitory signaling of the body. The number of cells 
within tissues is strongly regulated by both intracellular 
mechanisms, such as the induction of apoptosis and 
DNA repair, and by extracellular control, such as tumor 
suppression by the immune system. The occurrence of 
disordered proliferation, as in the case of cancer, occurs 
through a failure in the regulation of these mechanisms 
or through the development of malignant clones that 
escape from them6.
In general, the carcinogenic process is slow and may 
even be divided into three phases: initiation, promotion 
and progression. In the initiation phase, the cells are 
exposed to carcinogens that may promote cumulative 
changes or genetic instability. The promotion stage 
is characterized by the proliferation and selection of 
clones affected in the first phase. These cells start the 
process of malignant transformation characterized by 
the expression of oncogenes. At the stage of disease 
progression, preneoplastic cells develop into malignant 
neoplastic cells through a process of clonal expansion, 
which is facilitated by the progressive increase in 
genetic instability in these cells7. 
ORAL CANCER
Oral cancer refers to a subgroup of head and neck 
tumors that develop on the lips, tongue, salivary glands, 
gums, floor of mouth, hard palate, buccal mucosa and 
other intra-oral locations. These cancerous lesions are 
among the most prevalent forms of cancer in the world 
population8.
Oral cancer is the most common cancer among head 
and neck tumors, accounting for about one-third of 
all such tumors. According to current estimates, about 
275,000 new cases of oral cancer are diagnosed each 
year in the world9, 10. In addition to this high incidence, 
approximately 130,000 deaths per year are caused 
by this disease. The incidence of oral cancer in Latin 
America is approximately 4.6% of the population. 
However, most of the data for these statistics come from 
studies on Brazil, which complicates the description of 
the patterns of incidence in this continent11.
Oral cancer ranks eighth among the highest incidence of 
cancers in men worldwide2. Brazilian male population 
has the third biggest risk for the development of oral 
cancer, second only to France and India10. According 
to estimates by the National Cancer Institute (INCA)1, 
in Brazil, oral cancer is the fifth most frequent cancer 
among men and the sixth among women. In addition, 
more than 10,000 new cases of mouth cancer are 
diagnosed each year in this country.
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It is believed that the differences in incidence of tumors in 
the oral cavity in distinct populations are directly related 
to the different degrees of exposure to risk factors in these 
groups. In most countries around the world, oral cancer 
is more common in men than in women. The higher 
prevalence in men compared to women can be explained 
by their greater exposure to risk factors for oral cancer, 
such as tobacco, alcohol, and ultraviolet radiation from 
sunlight12. The proportion of men to women diagnosed 
with oral cancer; however, has diminished in recent 
decades and now it is about 1.5:113.
Risk factors for developing oral cancer are well 
established in the literature. The excessive consumption 
of alcohol and tobacco is considered the main etiological 
factor for the development of tumors in the mucosa 
and the exposure to solar ultraviolet radiation for lip 
cancers. Other factors such as diet composition, viral 
infections and hereditary factors are also considered 
potential risk factors9, 14-18.
In the oral cavity, approximately 90% of malignant 
lesions are carcinomas, which are tumors of epithelial 
origin. They can be identified and treated more easily 
in their early stages of development. Early diagnosis of 
these tumors can be accomplished with relative ease due 
to the accessibility of the oral cavity for examination. 
However, the vast majority of oral and oropharyngeal 
tumors are diagnosed at an advanced stage, which 
contributes to a survival rate of only five years. Even 
in developed countries, the rates have not improved in 
recent decades compared to other cancers19, 20.
Treatment for Oral Cancer
Although oral cancer represent a third of all malignant 
tumors of head and neck, their treatment options were 
not different in the last three decades. Frequently used 
therapies for the treatment of oral cancer include surgery, 
radiotherapy and chemotherapy. These treatments 
consist of removing the tumor completely and inducing 
lethal changes on both neoplastic and adjacent normal 
cells, through radiation and chemotherapy drugs. 
Choosing the most appropriate therapy depends on 
factors such as the tumor size, tumor staging, proximity 
to anatomical structures, involvement of the lymphatic 
chain, age and patient cooperation, and the histological 
subtype of the lesion20, 21.
Surgery is the treatment of choice for squamous cell 
carcinoma in early stages. In later stages of these lesions, 
the use of adjuvant radiotherapy or chemotherapy is 
recommended. The results obtained by these treatments 
indicate cure rates between 72 and 93% for tumors in 
early stage of progression. However, although they 
provide a good prognosis, these therapies cause post-
treatment complications that can affect aesthetics and 
function of the regions adjacent to the tumor, causing a 
sharp decrease in quality of life of patients22.
Even with the most modern procedures for surgical 
reconstruction, one of the consequences after the 
treatments is the occurrence of facial disfigurement, 
promoting serious cosmetic and functional defects. In 
such cases, severe psychological and emotional effects 
can also affect patient’s recovery, who often need an 
extended professional multidisciplinary follow-up to 
return to normal daily life8, 23.
Traditional treatments for oral cancer may lead 
to a broad spectrum of adverse effects to the 
maxillomandibular complex and associated structures. 
The most frequent complications related to radiotherapy 
are: mucositis, candidiasis, hyposalivation, radiation 
caries, dysphagia, taste loss, muscular trismus, vascular 
changes and osteoradionecrosis, which is the most 
serious complication24, 25. An exacerbation of infections 
such as periapical and periodontal diseases, and severe 
mucositis may, occasionally, demand an adjustment 
of treatment or the discontinuation of radiotherapy or 
chemotherapy, demonstrating that oral complications 
should be prevented or minimized.
Photodynamic Therapy
Based on the current therapeutic possibilities for 
the treatment of mouth neoplasms, several studies 
have demonstrated the use of photodynamic therapy 
(PDT) as an alternative for the treatment of a variety 
of malignancies, including oral cancer. In comparison 
with radiotherapy or chemotherapy, PDT is generally 
safer for the surrounding normal tissues because the 
photosensitizers are preferentially accumulated in tumor 
cells26,27. The great advantage in using this therapy is 
the reduction of side effects compared with other 
treatment modalities. Moreover, the application of PDT 
in the public health service has aroused great interest 
because, since PDT do not demand hospitalization, it 
presents lower operating cost compared to surgery and 
chemotherapy28.
Mechanisms of photochemical action
The principle of PDT is based on the use of two 
individually non-toxic components that are combined to 
induce cellular and tissue effects in an oxygen-dependent 
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manner. The first component is the photosensitizer, a 
photosensitive molecule that has affinity to neoplastic 
cells. The second component is a light source (laser or 
light emitting diodes - LED), with specific wavelength 
which activates the photosensitizer. This drug then 
transfers the energy from light to molecular oxygen, 
generating reactive oxygen species (ROS). These 
reactions occur at sites of immediate accumulation of 
the photosensitizer that absorbed the light. Therefore, 
the biological responses are activated only in specific 
areas of the tissue that were exposed to light29.
Photodynamic therapy is a multistep process involving 
the selective absorption of a photosensitizing drug 
by the tumor tissue, followed by the irradiation of 
the neoplastic lesion by a light source with specific 
wavelength. This radiation is capable of triggering 
photochemical reactions that generates singlet oxygen 
(1O2) and other reactive oxygen species (ROS). ROS 
generated by this process cause cytotoxic effects on 
tumor cells leading to tumor destruction. The drugs 
clinically used in PDT may bind the plasma membrane, 
intracellular membranes of the endoplasmic reticulum, 
mitochondria, lysosomes, or combinations of these 
sites. Once photosensitizers do not have the nucleus is 
a primary site to bind, such anti-cancer therapy can be 
considered less genotoxic if compared with radiotherapy 
or chemotherapy. The extent photodynamic of damage 
and cytotoxicity after PDT in vivo is multifactorial 
and depends on the type of photosensitizing agent 
used, its intracellular location, the time between the 
drug administration and the irradiation, as well as the 
different conditions of light irradiation. Moreover, the 
type of tumor and its level of oxygenation are crucial 
for the induction of photodynamic damage30.
Photodynamic effect can be demonstrated through two 
mechanisms called Type I and Type II. The processes 
involved in both mechanisms are shown in the Jablonski 
diagram (Figure 1).
After absorbing a photon, the molecule of the 
photosensitizer (PS) changes from the ground state 
(So) to the singlet excited state (S1). From this excited 
state, the PS can return to the ground state emitting a 
photon of energy through non-radioactive and radiative 
processes (fluorescence). The PS, in the excited state, 
can also reverse spontaneously its spin through the 
process of intersystem crossing and go from S1 to the 
triplet state (T1). Once formed, the T1 can undergo decay 
to the ground state via non-radioactive and radioactive 
processes (phosphorescence)30.
Figure 1: Jablonski diagram. 
The type I mechanism involves reactions of electron 
transfer between the molecule of the PS in their excited 
state S1 or T1 and the substrate. This process results in 
the formation of ion radicals that tend to react instantly 
with oxygen, producing a mixture of highly reactive 
oxygen intermediates like superoxide radical (•O2), 
hydrogen peroxide (H2O2) and hydroxyl radical (•OH), 
which oxidize a wide variety of biomolecules31.
The type II mechanism is characterized by reactions 
of energy transfer between the PS in the T1 state and 
molecular oxygen, which is also a triplet in the ground 
state (T0). These reactions lead to the formation of 
singlet oxygen (1O2), which is able to rapidly oxidize 
cell constituents and organelles resulting in the death of 
cancer cells31.
Both mechanisms may occur simultaneously. The 
proportion between them is highly influenced by 
the PS, the substrate, the oxygen concentration and 
the binding of PS to the substrate. However, type II 
mechanism seems to be more efficient because it has a 
higher rate constant than charge transfer reactions (type 
I mechanism). Consequently, the energy transferred to 
other compounds that can compete with oxygen is less 
important and the type II mechanism is often dominan31.
The singlet oxygen produced by a photochemical 
reaction is a highly reactive species, with electrophilic 
character. This ROS is able to induce oxidation of 
cellular molecules. Protein and unsaturated lipids are 
their main targets, resulting in irreversible damage to 
cellular organelles and cancer cells death. This reactive 
form of oxygen can also cause damage to the tumor 
vasculature, resulting an indirect form of tumor cell 
death, by hypoxia or starvation. In addition, damages in 
the cell membranes cause the release of inflammatory 
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mediators and immunological factors, which initiate a 
cascade of events responsible for cell death in several 
other tumor cells29.
Singlet oxygen has a short lifetime in biological systems 
(<0.04 µs) and a diffusion potential with a small radius 
of action (0.02 µm). Therefore, tissue damage resulting 
from photodynamic treatment is restricted to cancer 
cells and the penetration depth of light used to activate 
the photosensitizer29.
Since the interaction of singlet oxygen with organic 
molecules is not specific, any macromolecule within 
the cell may be a potential target for PDT. Therefore, 
due to the possible multiple targets, tumor cells hardly 
develop resistance to this treatment, which is one of the 
advantages of photosensitization. Other advantages of 
PDT refer to the possibility of repeating the procedure 
several times without the risk of cumulative toxicity in 
tissue, besides the possibility of retreatment with surgery 
or radiation therapy when such therapies are needed32.
Biological mechanisms involved in the 
Photodynamic Therapy
Dolmans et al. (2003) describe that the generation 
of reactive oxygen species (ROS) leads to tumor 
destruction by three main biological mechanisms: (1) 
direct destruction of tumor mass by the action of ROS, 
(2) damage to the tumor vasculature, creating areas of 
hypoxia in tumor masses and (3) reduction of tumor 
mass in a secondary phase as a result of the activation 
of the immune system by necrosis and / or apoptosis31.
ROS formed after the application of PDT are ionic 
molecules with high chemical activity and the potential 
to react with any biomolecule, stabilizing these chemical 
species. Due to the low diffusivity of ROS through 
cellular compartments, the cellular sites affected by PDT 
will be those where there was a selective accumulation 
of the photosensitizing drugs. Moreover, cellular sites 
where there is accumulation of the drugs are associated 
to physical and chemical characteristics of each class 
of drugs33.
Several histological studies have demonstrated that 
the application of PDT promotes tumor cells death by 
both mechanisms: necrosis and apoptosis. The large 
amount of ROS after PDT promotes numerous changes 
in the tumor cells. Tumor clones death may derive from 
mechanisms of apoptosis and necrosis, depending on 
the subcellular regions affected and on the intensity of 
the stimulus34.
Cell death by necrosis, in general, is related to the 
presence of an aggressive agent of high intensity, as 
the ROS formed after PDT. In this situation, the basic 
cellular mechanisms of defense and are ineffective. 
As striking features of necrosis, it is important to 
highlight the functional changes in different subcellular 
compartments, specially the disruption of biological 
membranes causing the release of cell content. In 
association with this process, membrane phospholipids 
are released, triggering an intense inflammation  through 
the lipooxigenase pathway35. 
Another cell death pathway is apoptosis, that occurs 
in both physiological and pathological events. The 
morphological events observed in cells undergoing 
apoptosis are chromatin condensation, packaging 
and release of cytoplasmic fragments and organelles 
in microvesicles wrapped in plasma membrane 
(the apoptotic bodies). The vesicles released are 
phagocytized by neighboring cells, triggering an 
inflammatory process in lower intensity compared 
to necrosis. Such lower refers to the non-release of 
membrane phospholipids. After PDT, the induction 
of apoptosis is less frequent than necrosis in cancer 
tissue36. 
The characterization of these two cell death processes, 
necrosis and apoptosis, can be performed with 
biochemical or morphological analysis. Numerous 
studies discuss the advantages and disadvantages of 
the occurrence of tumor cell death by each mechanism. 
This discussion is based on the stimulation or not of 
the immune system. Necrosis stimulates a greater 
immune response than apoptosis. Although the immune 
stimulation can induce adverse inflammatory events 
to patients, it can also promote the development of 
specific immune response against the treated tumors 
and regulate the tumor volume37. 
The second mechanism of tumor control post-PDT is 
the induction of vascular changes in the tumor areas. 
The major events reported are thrombosis and vessels 
occlusion, which promote the reduction and the 
collapse of the blood flow and consequent hypoxia in 
the tumor areas supplied by these vessels. The presence 
of inflammatory cells, platelet aggregation, vascular 
endothelial injury and necrosis areas enhance the 
development of thrombotic events after photodynamic 
therapy32. 
The third mechanism involved in the destruction of 
tumor masses is the action of the immune system 
against cancer cells. Contrary to other cancer therapies, 
PDT has an immunostimulating effect. A high activity 
of immune cells was observed in tumors treated with 
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PDT. Some authors also describe a systemic antitumor 
protective effect after PDT, related to the selection of 
memory T lymphocytes against tumor clones treated at 
the primary site of cancer37.
Photosensitizer Drugs
The photosensitizers (PS) are the main elements in the 
performance of PDT. These drugs are activated by the 
light energy to generate reactions that culminate in the 
formation of highly reactive chemical species, which 
promote the destruction of target cells29. 
A large number of PS has been clinically tested for 
PDT, but the results still suggest further research 
to develop more efficient PS. The prerequisites for 
an ideal PS include chemical purity, selectivity for 
tumor cells, chemical and physical stability, short 
time interval between the administration and the 
maximum accumulation in tumor tissues, activation at 
wavelengths with excellent tissue penetration and rapid 
excretion. The photophysical parameters desired are a 
high quantum yield of singlet oxygen as well as a high 
lifetime of the triplet state, because, in this case, the 
production of singlet oxygen is more effective38. 
The major classes of clinically used PS are shown in 
Table 1, each of these classes of drugs exhibit different 
photophysical and photochemical properties. 
Table 1: Main photosensitizers clinically used. Adapted from 
Allison et al., 201038.
Several factors must be observed to choose the best PS: 
toxicity and carcinogenicity of the drugs, selectivity for 
target cells; possible side effects after exposure to white 
light, route of administration, costs, drugs elimination, 
wavelength for activation and clinical effectiveness. 
A subjective combination of all these factors must be 
performed to justify the selection of the most appropriated 
PS among the various treatment options32, 39. 
Clinical application of PDT in Oral 
Cancer
PDT is already approved for clinical use in the United 
States, Canada, Russia, Japan and some European Union 
countries. In Brazil, this therapy is allowed for clinical 
research. For tumors of the mouth, the most widely used 
PS are Photofrin® (a porphyrin derivative) and Foscan® 
(an ALA derivative). More than 1500 cases of treatment 
of head and neck tumors with PDT have been reported. 
They were followed from 1990 to 2006. Clinically, this 
therapy has proven effective especially in cases of early 
tumors and precancerous lesions26. 
PDT is already approved for clinical use in the United 
States, Canada, Russia, Japan and some European 
Union countries. In Brazil, this therapy is allowed for 
clinical research. For tumors of the mouth, the most 
widely used PS are Photofrin® (a porphyrin derivative) 
and Foscan® (an ALA derivative). More than 1500 cases 
of treatment of head and neck tumors with PDT have 
been reported. They were followed from 1990 to 2006. 
Clinically, this therapy has proven effective especially 
in cases of early tumors and precancerous lesions26.
BIEL (2007), on a meta-analysis article, reports that 
among 518 patients with early tumors of head and neck 
(T1 or T2), 462 (89.1%) showed complete remission 
after a single treatment with PDT. In the same paper, 
the author describes that, in a 16-year follow-up of 171 
patients presenting larynx tumors treated with PDT, 
there was complete remission and no recurrence. These 
results are very encouraging for the use of PDT in the 
treatment of oral cancer, but follow-up studies of treated 
patients are still needed to establish the effectiveness of 
this therapy24. 
Although the PDT presents great advantages in the 
reduction of side effects commonly described after the 
traditional therapies for cancer, as described above, it 
can cause some other side effects that are mainly related 
to different patterns of skin phototoxicity26, 27.
Platform Drug Substance
Porphyrin Photofrin®, Photogem® HpDa
Porphyrin Levulan® ALAb
Porphyrin Metvix® M-ALAc
Porphyrin Hexvix® H-ALAd
Porphyrin Visudyne® Verteporfin
Texaphyrin Antrin®, Lu-Tex Lutexaphyrin
Chlorine Foscan® Temoporfin
Chlorine
LS11, Photolon®, 
LitxTM, ApoptosinTM, 
Laserphyrin
Talaporfin
Chlorine Photochlor HPPHc
Phthalocianines Photosens®, Pc4 Phthalocyanine
Padoporfin Tookad Bacteriochlorophyll
aHemtophorpyrin derivate, bAminolevulinic acid, cMethyl 
aminolevulinate, dHexaminolevulinate HCl
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CONCLUSION
Oral cancer accounts for about one third of all malignant 
tumors of head and neck and presents major challenges 
to optimize treatment options that limit morbidity 
and maximize the chances of cure. In this context, 
photodynamic therapy in has aroused great interest 
for its clinical application in the treatment of tumors 
in the oral cavity. The drastic reduction of the adverse 
effects of therapy, the conservative intervention and its 
simplicity are the major attractions of PDT. Currently, 
great hopes are placed in this method for treatment of 
cancer, but more careful long term studies are required 
to establish the real efficacy of this treatment protocol.
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